摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyrazine | 1011528-12-3

中文名称
——
中文别名
——
英文名称
3-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyrazine
英文别名
3-[(2-fluorophenyl)methyl]-2H-pyrazolo[3,4-b]pyrazine
3-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyrazine化学式
CAS
1011528-12-3
化学式
C12H9FN4
mdl
——
分子量
228.229
InChiKey
GHMATHZXPCZDDC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    54.5
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯-4,6-二氨基-1,3,5-三嗪3-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyrazinetris-(dibenzylideneacetone)dipalladium(0) caesium carbonate2-二环己基磷-2,4,6-三异丙基联苯 作用下, 以 甲苯 为溶剂, 反应 20.0h, 以6%的产率得到6-[3-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-1,3,5-triazine-2,4-diamine
    参考文献:
    名称:
    PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS
    摘要:
    本申请涉及新型氮杂双环化合物,其制备方法,它们单独或与其他物质结合用于治疗和/或预防疾病,以及用于生产治疗和/或预防疾病的药物,特别是用于治疗和/或预防心血管疾病。
    公开号:
    US20100029653A1
  • 作为产物:
    描述:
    2-chloro-3-[(2-fluorophenyl)ethynyl]pyrazine一水合肼 作用下, 以 正丁醇 为溶剂, 反应 0.5h, 以26%的产率得到3-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyrazine
    参考文献:
    名称:
    PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS
    摘要:
    本申请涉及新型氮杂双环化合物,其制备方法,它们单独或与其他物质结合用于治疗和/或预防疾病,以及用于生产治疗和/或预防疾病的药物,特别是用于治疗和/或预防心血管疾病。
    公开号:
    US20100029653A1
点击查看最新优质反应信息

文献信息

  • Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders
    申请人:Bayer Intellectual Property GmbH
    公开号:US08309551B2
    公开(公告)日:2012-11-13
    The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.
    本申请涉及新型杂环双环化合物、其制备过程,它们单独或组合使用用于治疗和/或预防疾病,以及它们用于制造治疗和/或预防疾病的药物,特别是用于治疗和/或预防心血管疾病。
  • US8309551B2
    申请人:——
    公开号:US8309551B2
    公开(公告)日:2012-11-13
  • [DE] PYRAZOLOPYRIDIN, INDAZOL, IMIDAZOPYRIDIN, IMIDAZOPYRIMIDIN, PYRAZOLOPYRAZIN UND PYRAZOLOPYRIDIN DERIVATE ALS STIMULATOREN DER GUANYLATCYCLASE ZUR HERZ-KREISLAUFERKRANKUNGEN<br/>[EN] PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS<br/>[FR] DÉRIVÉ DE PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE ET PYRAZOLOPYRIDINE EN TANT QUE STIMULANT DE LA GUANYLATCYCLASE POUR LES MALADIES CARDIOVASCULAIRES
    申请人:BAYER HEALTHCARE AG
    公开号:WO2008031513A1
    公开(公告)日:2008-03-20
    [EN] The present application relates to compounds of the formula (I) which act as stimulators of soluble guanylate cyclase and to their use for treatment and/or prevention of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, thromboembolic disorders and arteriosclerosis. L-CH2-M-Q (I) in which L is phenyl, pyridyl, furyl, thienyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl or (C5-C7)-cycloalkyl, M is a bicyclic heteroaryl group of the formula (a-1), (b-1) or (c-1), in which the attachment site to the group is -CH2-L, the attachment site to the group is Q, and A, B, D and E are each CH, CR1 or N, where not more than two of the ring members A, B, D and E are the same, and Q is an unsaturated or aromatic 5- or 6-membered heterocycle having up to four heteroatoms from the group of N, O and/or S.
    [FR] La présente invention concerne un composé de formule (I), qui agit en tant que stimulant de la guanylatcyclase soluble et son utilisation pour le traitement et/ou la prévention de l'insuffisance cardiaque, de l'angine de poitrine, de l'hypertonie, de l'hypertonie pulmonaire, de l'ischémie, des angiopathies, des maladies thromboemboliques et de l'artériosclérose. L-CH2-M-Q (I) dans laquelle L représente phényle, pyridyle, furyle, thiényle, thiazolyle, oxazolyle, isothiazolyle, isoxazolyle ou un cycloalkyle en (C5-C7), M représente un groupement hétéroaryle de formule (a-1), (b-1) ou (c-1), le site de liaison représentant le groupement -CH2-L, le site de liaison représentant le groupement Q, A, B, D et E représentant chacun CH, CR1 ou N. Selon l'invention, au plus deux des éléments cycliques A, B, D et E sont identiques et Q représente un hétérocycle insaturé ou aromatique ayant 5 ou 6 éléments, avec jusqu'à quatre hétéroatomes de la série N, O et/ou S.
    [DE] Die vorliegende Anmeldung betrifft Verbindung der Formel (I), die als Simulatoren der löslichen Guanylatcyclase wirken und ihre Verwendung zur Behandlung und/oder Prävention von Herzinsuffizienz, Angina pectoris, Hypertonie, pulmonaler Hypertonie, Ischämien, Gefässerkrankungen, thromboembolischen Erkrankungen und Arteriosklerose. L-CH2-M-Q (I) in welcher L für Phenyl, Pyridyl, Furyl, Thienyl, Thiazolyl, Oxazolyl, Isothiazolyl, Isoxazolyl oder (C5-C7)-Cycloalkyl, M für eine bicyclische Heteroaryl-Gruppe der Formel (a-1), (b-1) oder (c-1) steht, worin die Verknüpfungsstelle mit der Gruppe -CH2-L bedeutet, die Verknüpfungsstelle mit der Gruppe Q bedeutet, A, B, D und E jeweils CH, CR1 oder N bedeuten, wobei maximal zwei der Ringglieder A, B, D und E zugleich stehen, und Q für einen ungesättigten oder aromatischen 5- oder 6-gliedrigen Heterocyclus mit bis zu vier Heteroatomen aus der Reihe N1 O und/oder S steht.
  • PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS
    申请人:Schirok Hartmut
    公开号:US20100029653A1
    公开(公告)日:2010-02-04
    The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.
    本申请涉及新型氮杂双环化合物,其制备方法,它们单独或与其他物质结合用于治疗和/或预防疾病,以及用于生产治疗和/或预防疾病的药物,特别是用于治疗和/或预防心血管疾病。
查看更多

同类化合物

S-(1-乙烯基-1H-吡唑并[3,4-b]吡嗪-5-基)乙硫酸酯 6-甲基-1H-吡唑并[3,4-b]吡嗪-3-醇 6-氯-1H-吡唑并[3,4-B]吡嗪 6-氨基-1,3-二甲基-1H-吡唑并[3,4-b]吡嗪-5-甲腈 5-甲基-1H-吡唑并[3,4-b]吡嗪-3-醇 5-溴-3-甲基-1H-吡唑并[3,4-b]吡嗪 5-溴-1H-吡唑并[3,4-b]吡嗪-3-胺 4,7-二氮杂-1H-吲唑 3-甲基-1H-吡唑并[3,4-b]吡嗪 3-溴-1H-吡唑并[3,4-B]吡嗪 3,6-二氨基-1H-吡唑并[3,4-b]吡嗪-5-甲腈 2-(1H-吡唑并[3,4-b]吡嗪-5-基氨基)乙醇 2,3,6,7-四氢-3,6-二氧代-1H-吡唑并[3,4-b]吡嗪-5-甲腈 1H-吡唑并[3,4-B]吡嗪-3-氨基 1-甲基吡唑并[3,4-b]吡嗪-3-胺 1-甲基-1,2-二氢-3H-吡唑并[3,4-b]吡嗪-3-酮 1-(6-羟基-1,3-二甲基-1H-吡唑并[3,4-b]吡嗪-5-基)-乙酮 1-(1,3,6-三甲基-1H-吡唑并[3,4-b]吡嗪-5-基)-乙酮 1,5,6-三甲基-1H-吡唑并[3,4-b]吡嗪 1,5,6-三甲基-1,2-二氢-3H-吡唑并[3,4-b]吡嗪-3-酮 1,3-dimethyl-6-phenylpyrazolo<3,4-b>pyrazine 4-oxide ethyl 6-methoxy-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-1H-pyrazolo[3,4-b]pyrazine-3-carboxylate ethyl 6-chloro-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-1H-pyrazolo[3,4-b]pyrazine-3-carboxylate 1-(1-ethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-1H-pyrazolo[3,4-b]pyrazine 1-(1-Ethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyrazine 1,7-diacetonyl-3,5-dinitrodipyrazolo<3,4-b;4',3'-e>pyrazine trifluoro-methanesulfonic acid 3-[6-ethyl-1-(2-methoxy-1-methyl-ethyl)-3-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl]-6-isopropyl-pyridin-2-yl ester 6-ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-1-(2-methoxy-1-methyl-ethyl)-3-methyl-1H-pyrazolo[3,4-b]pyrazine 6-(4-methoxyphenyl)-1,3-dimethylpyrazolo<3,4-b>pyrazin-5(4H)-one 3-{[(2S)-2-amino-3-(3-thienyl)propyl]oxy}-6-(2-methyl-3-furanyl)-5-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-2-pyridinamine 3-(3-(difluoromethoxy)pyridin-2-yl)-1-methyl-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine 1-methyl-6-(pyridin-2-ylmethoxy)-3-(4-methyl-pyridazin-3-yl)-1H-pyrazolo[3,4-b]pyrazine 1-methyl-3-(3-methylpyridin-2-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine 6-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyrazin-5(4H)-one 1,3,6-trimethyl-1H-pyrazolo[3,4-b]pyrazin-5(4H)-one 1-benzyl-1,2-dihydro-pyrazolo[3,4-b]pyrazin-3-one 5,6-diphenyl-1,2-dihydro-pyrazolo[3,4-b]pyrazin-3-one 6-benzyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyrazin-5(4H)- 1H,7H-dipyrazolo<3,4-b;4',3'-e>pyrazine 4H-Pyrazolo[3,4-b]pyrazin-4-ol 5,6-dimethyl-1,2-dihydro-pyrazolo[3,4-b]pyrazin-3-one 3-(6-chloropyridin-2-yl)-1H-pyrazolo[3,4-b]pyrazine 2-(1H-Pyrazolo[3,4-b]pyrazin-1-yl)ethanol 1,1-dimethylethyl [(1S)-2-{[2-amino-6-(2-methyl-3-furanyl)-5-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-5-yl)-3-pyridinyl]oxy}-1-(3-thienylmethyl)ethyl]carbamate [(S)-1-(2-Methyl-propane-1-sulfonyl)-piperidin-3-yl]-[3-(1H-pyrazolo[3,4-b]pyrazin-5-yl)-pyridin-2-yl]-amine N-[(3S)-1-(2-methylpropylsulfonyl)piperidin-3-yl]-3-[1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyrazin-5-yl]pyridin-2-amine 1,3-dimethyl-5-oxo-4,5-dihydro-1H-dipyrazolo[1,5-a;4',3'-e]pyrazine-6-carboxylic acid 3-(1,5-dimethyl-1H-pyrazol-4-yl)-1-methyl-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine 6-(4-chlorophenyl)-1,3-dimethylpyrazolo<3,4-b>pyrazine 4-oxide 5-acetoxy-6-(4-chlorophenyl)-1,3-dimethylpyrazolo<3,4-b>pyrazine